Fmr LLC Decreases Holdings in Selecta Biosciences Inc (SELB)

Fmr LLC cut its stake in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 33.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 279,423 shares of the company’s stock after selling 139,556 shares during the period. Fmr LLC’s holdings in Selecta Biosciences were worth $3,702,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rhumbline Advisers raised its stake in Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after buying an additional 5,103 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Selecta Biosciences by 37.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock valued at $447,000 after buying an additional 9,100 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Selecta Biosciences by 27.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after buying an additional 10,114 shares during the last quarter. A.R.T. Advisors LLC raised its stake in Selecta Biosciences by 225.5% during the 1st quarter. A.R.T. Advisors LLC now owns 59,584 shares of the company’s stock valued at $607,000 after buying an additional 41,277 shares during the last quarter. Finally, Wasatch Advisors Inc. raised its stake in Selecta Biosciences by 9.2% during the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock valued at $3,122,000 after buying an additional 19,803 shares during the last quarter. Institutional investors and hedge funds own 48.74% of the company’s stock.

Shares of SELB stock opened at $14.23 on Friday. Selecta Biosciences Inc has a 1 year low of $7.95 and a 1 year high of $24.02. The company has a quick ratio of 4.96, a current ratio of 4.96 and a debt-to-equity ratio of 0.87. The firm has a market cap of $348.26 million, a PE ratio of -4.24 and a beta of -3.47.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). On average, sell-side analysts forecast that Selecta Biosciences Inc will post -3.07 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on the stock. BidaskClub lowered shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Stifel Nicolaus assumed coverage on shares of Selecta Biosciences in a research note on Friday, September 14th. They set a “buy” rating and a $24.00 target price for the company. Canaccord Genuity reiterated a “buy” rating and set a $40.00 target price on shares of Selecta Biosciences in a research note on Wednesday, July 11th. Zacks Investment Research lowered shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Finally, Mizuho reiterated a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a research note on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $27.40.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Further Reading: Trading Strategy Methods and Types

Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences Inc (NASDAQ:SELB).

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply